Oscient Pharma (OSCI) Says FDA Committee will Review sNDA for FACTIVE Tablets for Treatment of ABS
Tweet Send to a Friend
The U.S. Food and Drug Administration (FDA) has informed Oscient Pharmaceuticals (Nasdaq: OSCI) that the FDA's Anti-Infective Drugs Advisory Committee ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
